The novel meningococcal serogroup B vaccine (4CMenB, Bexsero(®)), recently approved in Europe and Australia, may soon be included in routine infant immunization schedules, subject to guidance from national or regional recommending bodies. In the development of 4CMenB and consistent with other newly introduced vaccines, clinical studies have shown concomitant administration with routine infant vaccines induces an incremental increase in some reactions, including fever. As this may hinder acceptability, we examined the impact of prophylactic paracetamol on the occurrence of fever and other solicited reactions, as well as the immune responses to study vaccines, in a prospectively designed study. 4CMenB was administered as a 4-dose series at 2, 3, 4, and 12 months of age concomitantly with routine infant vaccines: DTaP-HBV-IPV/Hib and PCV7, with or without prophylactic paracetamol; a third group received MenC vaccine. Immune responses to 4CMenB were not decreased by the use of paracetamol prophylaxis and there were no clinically relevant effects on immune responses to routine vaccines. Occurrence of fever was higher in infants co-administered with 4CMenB compared with those given MenC vaccine, but was significantly decreased by prophylactic paracetamol, as were other solicited reactions to vaccination, both local and systemic. Co-administration of 4CMenB had an acceptable tolerability profile, with no withdrawals due to vaccination-related adverse events. Inclusion of 4CMenB in routine infant immunization schedules will be a major advance in the control of meningococcal disease, and our study indicates that by using paracetamol prophylaxis, post-vaccination reactions are reduced without clinically relevant negative consequences on vaccine immunogenicity.

University Hospital Hradec Kralove; Hradec Kralove Czech Republic

Zobrazit více v PubMed

Crocetti M, Moghbeli N, Serwint J. Fever phobia revisited: have parental misconceptions about fever changed in 20 years? Pediatrics. 2001;107:1241–6. doi: 10.1542/peds.107.6.1241. PubMed DOI

Sullivan JE, Farrar HC, Section on Clinical Pharmacology and Therapeutics. Committee on Drugs Fever and antipyretic use in children. Pediatrics. 2011;127:580–7. doi: 10.1542/peds.2010-3852. PubMed DOI

Centers for Disease Control (CDC) Pertussis immunization; family history of convulsions and use of antipyretics--supplementary ACIP statement. MMWR Morb Mortal Wkly Rep. 1987;36:281–2. PubMed

Ipp MM, Gold R, Greenberg S, Goldbach M, Kupfert BB, Lloyd DD, Maresky DC, Saunders N, Wise SA. Acetaminophen prophylaxis of adverse reactions following vaccination of infants with diphtheria-pertussis-tetanus toxoids-polio vaccine. Pediatr Infect Dis J. 1987;6:721–5. doi: 10.1097/00006454-198708000-00005. PubMed DOI

Lewis K, Cherry JD, Sachs MH, Woo DB, Hamilton RC, Tarle JM, Overturf GD. The effect of prophylactic acetaminophen administration on reactions to DTP vaccination. Am J Dis Child. 1988;142:62–5. PubMed

Jackson LA, Peterson D, Dunn J, Hambidge SJ, Dunstan M, Starkovich P, Yu O, Benoit J, Dominguez-Islas CP, Carste B, et al. A randomized placebo-controlled trial of acetaminophen for prevention of post-vaccination fever in infants. PLoS One. 2011;6:e20102. doi: 10.1371/journal.pone.0020102. PubMed DOI PMC

Prymula R, Siegrist CA, Chlibek R, Zemlickova H, Vackova M, Smetana J, Lommel P, Kaliskova E, Borys D, Schuerman L. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet. 2009;374:1339–50. doi: 10.1016/S0140-6736(09)61208-3. PubMed DOI

Uhari M, Hietala J, Viljanen MK. Effect of prophylactic acetaminophen administration on reaction to DTP vaccination. Acta Paediatr Scand. 1988;77:747–51. doi: 10.1111/j.1651-2227.1988.tb10741.x. PubMed DOI

Long SS, Deforest A, Smith DG, Lazaro C, Wassilak GF. Longitudinal study of adverse reactions following diphtheria-tetanus-pertussis vaccine in infancy. Pediatrics. 1990;85:294–302. PubMed

Prymula R, Habib A, François N, Borys D, Schuerman L. Immunological memory and nasopharyngeal carriage in 4-year-old children previously primed and boosted with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) with or without concomitant prophylactic paracetamol. Vaccine. 2013;31:2080–8. doi: 10.1016/j.vaccine.2013.01.044. PubMed DOI

Halperin SA, Bettinger JA, Greenwood B, Harrison LH, Jelfs J, Ladhani SN, McIntyre P, Ramsay ME, Sáfadi MA. The changing and dynamic epidemiology of meningococcal disease. Vaccine. 2012;30(Suppl 2):B26–36. doi: 10.1016/j.vaccine.2011.12.032. PubMed DOI

Findlow J, Borrow R, Snape MD, Dawson T, Holland A, John TM, Evans A, Telford KL, Ypma E, Toneatto D, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis. 2010;51:1127–37. doi: 10.1086/656741. PubMed DOI

Snape MD, Dawson T, Oster P, Evans A, John TM, Ohene-Kena B, Findlow J, Yu LM, Borrow R, Ypma E, et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J. 2010;29:e71–9. PubMed

Gossger N, Snape MD, Yu L-M, Finn A, Bona G, Esposito S, Principi N, Diez-Domingo J, Sokal E, Becker B, et al. Immunogenicity and tolerability of recombinant meningococcal serogroup B vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA. 2012;307:573–82. doi: 10.1001/jama.2012.85. PubMed DOI

Vesikari T, Esposito S, Prymula R, Ypma E, Kohl I, Toneatto D, Dull P, Kimura A, EU Meningococcal B Infant Vaccine Study group Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet. 2013;381:825–35. doi: 10.1016/S0140-6736(12)61961-8. PubMed DOI

Esposito S, Roman Prymula R, Zuccotti GV, Kittel C, Toneatto D, Kohl I, Dull P. A phase 2 randomised controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II): effects of variations of the OMV and protein content on immunogenicity and reactogenicity. Hum Vaccin Immunother. 2014 Forthcoming. PubMed PMC

Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine. 2009;27(Suppl 2):B112–6. doi: 10.1016/j.vaccine.2009.04.065. PubMed DOI

Bonhoeffer J, Bentsi-Enchill A, Chen RT, Fisher MC, Gold MS, Hartman K, Heininger U, Hoet B, Jefferson T, Khuri-Bulos N, et al. Brighton Collaboration Methods Working Group Guidelines for collection, analysis and presentation of vaccine safety data in surveillance systems. Vaccine. 2009;27:2289–97. doi: 10.1016/j.vaccine.2008.11.035. PubMed DOI

Chen RT, Clark TA, Halperin SA. The yin and yang of paracetamol and paediatric immunisations. Lancet. 2009;374:1305–6. doi: 10.1016/S0140-6736(09)61802-X. PubMed DOI

Heininger U, Sänger R, Jacquet J-M, Schuerman L, DTP-HBV-IPV-059 Study Group. DTP-HBV-IPV-096 Study Group Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses. Vaccine. 2007;25:1055–63. doi: 10.1016/j.vaccine.2006.09.060. PubMed DOI

Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med. 2010;362:1511–20. doi: 10.1056/NEJMra0906357. PubMed DOI

Finne J, Bitter-Suermann D, Goridis C, Finne U. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol. 1987;138:4402–7. PubMed

Sullivan JE, Farrar HC, Section on Clinical Pharmacology and Therapeutics. Committee on Drugs Fever and antipyretic use in children. Pediatrics. 2011;127:580–7. doi: 10.1542/peds.2010-3852. PubMed DOI

Bjune G, Høiby EA, Grønnesby JK, Arnesen O, Fredriksen JH, Halstensen A, Holten E, Lindbak AK, Nøkleby H, Rosenqvist E, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet. 1991;338:1093–6. doi: 10.1016/0140-6736(91)91961-S. PubMed DOI

Holst J, Martin D, Arnold R, Huergo CC, Oster P, O’Hallahan J, Rosenqvist E. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine. 2009;27(Suppl 2):B3–12. doi: 10.1016/j.vaccine.2009.04.071. PubMed DOI

O’Hallahan J, McNicholas A, Galloway Y, O’Leary E, Roseveare C. Delivering a safe and effective strain-specific vaccine to control an epidemic of group B meningococcal disease. N Z Med J. 2009;122:48–59. PubMed

Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213–26. doi: 10.1002/sim.4780040211. PubMed DOI